Slingshot members are tracking this event:

Ardelyx, Inc. to Submit Detailed Results from Its First Phase 3 Trial Of Tenapanor for Hyperphosphatemia in End-Stage Renal Disease (ESRD) at The American Society Of Nephrology Kidney Week

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ARDX Community voting in process
KERX Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Tenapanor, End-stage Renal Disease, Esrd, Hyperphosphatemia